Videos

Search

Saved Activities

 x 

0 Activities
0 Activities

Achieving Better Control of Severe Asthma

Array

Activity Info

This education identifies the most current strategies for diagnosing severe asthma and the criteria describing the type 2 asthma phenotype. This information will be reinforced by case studies, case-based decision-making, and doctor-patient videos.
Email

Activity Title: Achieving Better Control of Severe Asthma : New Understanding in Asthma Pathophysiology and Targeted Therapies

Accreditation Type: AMA PRA Category 1 Credit(s)™/MOC Points

Release Date: 4/10/18

Expiration Date: 4/9/19

Estimated Time to Complete Activity: 1 hour

 

LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

  • Describe a thorough assessment of asthma severity and control in day-to-day practice
  • Explain how mechanisms of action in new/emerging type 2 inflammation-directed treatments address the underlying immunology of asthma
  • Select appropriate type 2 inflammation-targeted therapies on the basis of safety and efficacy data, and phenotype

FACULTY

Nicola A. Hanania, MD, MS

Baylor College of Medicine

Houston, Texas

Monica Kraft, MD

University of Arizona College of Medicine

Tucson, Arizona

 

MOC REVIEWERS

Theodore Bruno, MD, FACEHP 

Chief Medical Officer

The France Foundation

Old Lyme, Connecticut

Thomas B. Casale, MD 

University of South Florida

Tampa, Florida

 

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

  1. There are no fees for participating in and receiving credit for this activity. 
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity 
  4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  6. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards. 

ACCREDITED PROVIDER
This activity is provided by The France Foundation.

 

TARGET AUDIENCE

This activity is intended for allergists/immunologists and pulmonologists.

 

ACCREDITATION STATEMENT 

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

CREDIT DESIGNATION

Physicians: The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Maintenance of Certification: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

 

DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

 

Activity Staff Disclosures 

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

 

Faculty Disclosures

The following faculty report that they have relevant financial relationships to disclose: 

  • Theodore Bruno, MD, FACEHP, and his spouse are shareholders in Allergen and have received financial support from Allergen.
  • Thomas B. Casale, MD, has served on the advisory board for AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, Novartis, Sanofi Genzyme and Regeneron Pharmaceuticals, and Teva Pharmaceutical Industries Ltd.
  • Nicola Hanania, MD, has received honoraria for serving on advisory boards and as consultant for AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Novartis, Roche, and Sanofi/Regeneron. He has also received research grant support from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, and Roche.
  • Monica Kraft, MD, has received grant support from NIH, Chiesi, Sanofi/Regeneron and Roche. She has received honoraria for serving on advisory boards as a consultant for Sanofi/Regeneron, TEVA and AstraZeneca.

DISCLOSURE OF UNLABELED USE

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information. 

 

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This educational activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

 

DISCLAIMER 

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter assume no liability for the information herein.

 

COPYRIGHT INFORMATION
Copyright © 2018 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions: 

  • The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered. 
  • Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission. 

 

PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

CONTACT INFORMATION

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Tags

Video | Pulmonary | MOC | CME (AMA PRA Category 1 Credit) | 1.0 - 60 mins | Interactive Case | Allergy/Clinical Immunology | Internal Medicine | Family Medicine | Asthma | PILOTforPulmonary.org | Online |